[en] Neuroendocrine neoplasms are histologically defined by a common neuroendocrine cellular phenotype. These are still considered as rare tumours even though their incidence is increasing. Heterogeneity is everywhere whether in the localization of the primitive cancer, the clinical presentation, the histological classification, the prognosis, as well as in therapeutic options, which clearly justifies specialized multidisciplinary care. Heterogeneity and scarcity explain the still fragmented nature of knowledge in this domain. Thanks to an increase in incidence, a desire for standardization of classification as well as the arrival of major therapeutic advances, such as vectorized internal radiotherapy, the future of neuroendocrine neoplasia seems more than promising and exciting. In our daily clinical practice at CHU Liège, we hope to bring our stone to the building by listing as many cases as possible in national and/or international databases, by centralizing therapeutic discussions within specific multidisciplinary concertations and by participating in multicenter study protocols. [fr] Les néoplasies neuroendocrines sont définies histologiquement par un phénotype cellulaire neuroendocrine commun. Ces néoplasies sont toujours considérées comme des tumeurs rares, bien que leur incidence soit en constante augmentation. L’hétérogénéité est omniprésente, que ce soit dans la localisation du cancer primitif, la présentation clinique, la classification histologique, le pronostic ainsi que dans les diverses options thérapeutiques, justifiant impérativement une prise en charge pluridisciplinaire spécialisée. Cette hétérogénéité et cette rareté expliquent que les connaissances soient parcellaires. Grâce à une majoration d’incidence, une volonté d’uniformisation de classification ainsi que l’arrivée d’avancées thérapeutiques majeures, telles que la radiothérapie interne vectorisée, l’avenir des néoplasies neuroendocrines semble plus que prometteur et palpitant. En pratique clinique quotidienne au CHU de Liège, nous espérons apporter notre pierre à l’édifice en recensant un maximum de cas dans des bases de données nationales et/ou internationales, en centralisant les discussions thérapeutiques au sein de concertations multidisciplinaires dédiées et en participant à des protocoles d’études cliniques multicentriques.
Disciplines :
Endocrinology, metabolism & nutrition Oncology
Author, co-author :
Lousberg, Laurent ; Université de Liège - ULiège > Centres généraux > ISLV : Enseignements et formations complémentaires/extérieures des langues étrangères
Collignon, Joëlle ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Troisfontaine, Florence ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
PAULUS, Astrid ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
VAILLANT, Frédérique ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
DELANNOY, Pauline ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique
Petignot, Sandrine ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique
Petrossians, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique
Rohmer, Vincent ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Jadoul, Alexandre ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
Beckers, Albert ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique
Language :
French
Title :
Néoplasies neuroendocrines : une nouvelle ère a l’apogée de la multidisciplinarité !
Alternative titles :
[en] Neuroendocrine neoplasms : a new era to the top of multidisciplinarity !
Klöppel G. Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol 2007;18:141-4.
Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005;19:491-505.
Rindi G, Inzani F. Neuroendocrine neoplasm update: toward universal nomenclature. Endocr Relat Cancer 2020;27:R211-R8.
Masson P. Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of the appendicular mucosa. Am J Pathol 1928;4:181-212.
Pearse AG. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17:303-13.
Capella C, Heitz PU, Höfler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-60.
Klimstra DS, Klöppel G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. Dans: WHO classification of tumours Editorial Board. WHO Classification of Tumours. Digestive System Tumours. 5th ed. WHO;2019:16-22.
Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770-86.
O'Shea T, Druce M. When should genetic testing be performed in patients with neuroendocrine tumours ? Rev Endocr Metab Disord 2017;18:499-515.
Belgian Cancer Registry. En ligne: www.kankerregister.org - Dernière consultation le 16/03/2021.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335-42.
Yao JC, Hassan M, Phan A, et al. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008;26:3063-72.
de Mestier L, Cros J, Neuzillet C, et al. Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms. Neuroendocrinology 2017;105:412-25.
Clement D, Ramage J, Srirajaskanthan R. Update on pathophysiology, treatment, and complications of carcinoid syndrome. J Oncol 2020;2020:8341426.
Davar J, Connolly HM, Caplin ME, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol 2017;69:1288-304.
Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119.
Taïeb D, Hicks RJ, Hindié E, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2019;46:2112-37.
Nölting S, Ullrich M, Pietzsch J, et al. Current management of pheochromocytoma/paraganglioma: a guide for the practicing clinician in the era of precision medicine. Cancers (Basel) 2019;11:1505.
Société nationale française de gastroentérologie. Thésaurus national de cancérologie digestive. http://www.tncd.org - Dernière consultation le 16/03/2021.
de Mestier L, Deguelte-Lardière S, Brixi H, et al. Digestive neuroendocrine tumors. Rev Med Interne 2016;37:551-60.
Balogova S, Talbot JN, Nataf V, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging 2013;40:943-66.
O'Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 2009;90:194-202.
Pavel M, O'Toole D, Costa F, et al. ENETS Consensus Guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172-85.
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:844-60.
Baudin E, Caplin M, Garcia-Carbonero R, et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;S0923-7534(21)00011-9.
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224-33.
Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
de Mestier L, Couvelard A, Blazevic A, et al. Critical appraisal of MGMT in digestive NET treated with alkylating agents. Endocr Relat Cancer 2020;27:R391-R405.
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo- controlled, phase 3 study. Lancet 2016;387:968-77.
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate fort the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017;376:125-35.
Ramage J, Naraev BG, Halfdanarson TR. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. Semin Oncol 2018;45:236-48.
